EP3000894 - Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 24.02.2017 Database last updated on 31.08.2024 | |
Former | The application has been published Status updated on 07.11.2016 | Most recent event Tooltip | 24.02.2017 | Application deemed to be withdrawn | published on 29.03.2017 [2017/13] | Applicant(s) | For all designated states Universitätsklinikum Regensburg Franz-Josef-Strauss-Allee 11 93053 Regensburg / DE | [2016/13] | Inventor(s) | 01 /
Geissler, Edward Kastanienweg 14 93173 Regensburg / DE | 02 /
Mycielska, Maria Maria-Herbert-Str. 23/1 93051 Regensburg / DE | 03 /
Ruemmele, Petra Mattingerstrasse 10 93049 Regensburg / DE | [2016/13] | Representative(s) | Isarpatent Patent- und Rechtsanwälte Barth Charles Hassa Peckmann & Partner mbB Friedrichstrasse 31 80801 München / DE | [N/P] |
Former [2016/13] | Isarpatent Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann & Partner mbB Friedrichstrasse 31 80801 München / DE | Application number, filing date | 14186315.9 | 25.09.2014 | [2016/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3000894 | Date: | 30.03.2016 | Language: | EN | [2016/13] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.04.2015 | Classification | IPC: | C12Q1/68, G01N33/574 | [2016/13] | CPC: |
C12Q1/6886 (EP,US);
G01N33/5011 (US);
C07K16/18 (EP,US);
G01N33/57492 (EP,US);
A61K2039/505 (EP,US);
C07K2317/76 (US);
C12Q2600/158 (EP,US);
G01N2500/04 (EP,US);
G01N2500/10 (US);
G01N2800/56 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/13] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | Plasmamembrancitrattransporter zur Verwendung bei der Diagnose und Behandlung von Krebs | [2016/13] | English: | Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer | [2016/13] | French: | Transporteur de citrate de membrane plasmique à utiliser dans le diagnostic et le traitement du cancer | [2016/13] | Examination procedure | 01.10.2016 | Application deemed to be withdrawn, date of legal effect [2017/13] | 08.11.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2017/13] | Fees paid | Penalty fee | Additional fee for renewal fee | 30.09.2016 | 03   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2004100885 (UNIV PENNSYLVANIA [US], et al) [X] 4-7 * claims 42-44,52 *; | [X]WO2014066320 (UNIV GEORGETOWN [US]) [X] 4-7,11 * page 14; claims 1-10 *; | [Y] - MACIEJ P MAZUREK ET AL, "Molecular origin of plasma membrane citrate transporter in human prostate epithelial cells", EMBO REPORTS, (20100507), vol. 11, no. 6, doi:10.1038/embor.2010.51, ISSN 1469-221X, pages 431 - 437, XP055178640 [Y] 1-14 * page 432 - page 434 * DOI: http://dx.doi.org/10.1038/embor.2010.51 | [Y] - Vamsi K Kolukula ET AL, "SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker", Oncotarget, United States, (20140315), page 1212, URL: http://www.ncbi.nlm.nih.gov/pubmed/24681808, XP055178880 [Y] 1-14 * abstract * * page 1217 * DOI: http://dx.doi.org/10.18632/oncotarget.1831 | [A] - PHILIPPE ICARD ET AL, "Understanding the central role of citrate in the metabolism of cancer cells", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - REVIEWS ON CANCER, (20120101), vol. 1825, no. 1, doi:10.1016/j.bbcan.2011.10.007, ISSN 0304-419X, pages 111 - 116, XP055178685 [A] 1-14 * abstract * DOI: http://dx.doi.org/10.1016/j.bbcan.2011.10.007 | [A] - MARIA E. MYCIELSKA ET AL, "Citrate transport and metabolism in mammalian cells", BIOESSAYS, (20090101), vol. 31, no. 1, doi:10.1002/bies.080137, ISSN 0265-9247, pages 10 - 20, XP055178985 [A] 1-14 * the whole document * DOI: http://dx.doi.org/10.1002/bies.080137 | [A] - VINCENZA DOLCE ET AL, "Mitochondrial tricarboxylate and dicarboxylate-Tricarboxylate carriers: from animals to plants", IUBMB LIFE, (20140701), vol. 66, no. 7, doi:10.1002/iub.1290, ISSN 1521-6543, pages 462 - 471, XP055179157 [A] 1-14 * page 466 * DOI: http://dx.doi.org/10.1002/iub.1290 | [A] - MARIA E. MYCIELSKA ET AL, "Expression of Na + -dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na + channel activity", THE JOURNAL OF PHYSIOLOGY, (20050221), vol. 563, no. 2, doi:10.1113/jphysiol.2004.079491, ISSN 0022-3751, pages 393 - 408, XP055178999 [A] 1-14 * the whole document * DOI: http://dx.doi.org/10.1113/jphysiol.2004.079491 | by applicant | - DITTRICH ET AL., "Prostate cancer growth and citrate levels", PROSTATE CANCER AND PROSTATIC DISEASES, (2012), vol. 15, pages 278 - 282 | - MYCIELSKA ET AL., "Expression of Na+-dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na+ channel activity", J PHYSIOL., (20050301), vol. 56, page 8 | - MAZUREK ET AL., "Molecular origin of plasma membrane citrate transporter in human prostate epithelial cells", EMBO REP., (201006), vol. 11, no. 6, doi:doi:10.1038/embor.2010.51, pages 431 - 7, XP055178640 DOI: http://dx.doi.org/10.1038/embor.2010.51 | - JEREMY BERG; JOHN TYMOCZKO; LUBERT STRYER, Biochemistry | - TEICHER ET AL., "Antibody Conjugate Therapeutics: Challenges and Potential", CLIN CANCER RES, (2011), vol. 17, doi:doi:10.1158/1078-0432.CCR-11-1417, pages 6389 - 6397, XP055067528 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-11-1417 | - "Production of Polyclonal Antisera", GREEN, Immunochemical Protocols, HUMANA PRESS, (1992), pages 1 - 5 | - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497 | - KOZBOR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, page 2 | - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1985), pages 77 - 96 | - SUN ET AL., "Mitochondrial and Plasma Membrane Citrate Transporters: Discovery of Selective Inhibitors and Application to Structure/Function Analysis", MOL CELL PHARMACOL., (2010), vol. 2, no. 3, pages 101 - 110, XP055093800 | - MIZUNO ET AL., "Impact of Drug Transporter Studies on Drug Discovery and Development", PHARMACOLOGICAL REVIEWS, (2003), vol. 55, doi:doi:10.1124/pr.55.3.1, pages 425 - 461, XP002612395 DOI: http://dx.doi.org/10.1124/pr.55.3.1 | - VANDER HEIDEN, M.G.; CANTLEY, L.C.; THOMPSON, C.B., "Understanding the Warburg effect: the metabolic requirements of cell proliferation", SCIENCE, (2009), vol. 324, pages 1029 - 1033 | - CURRIE, E.; SCHULZE, A.; ZECHNER, R.; WALTHER, T.C.; FARESE, R.V. JR., "Cellular Fatty Acid metabolism and cancer", CELL. METAB., (2013), vol. 18, pages 153 - 161 | - LIU, Y., "Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer", PROSTATE CANCER PROSTATIC DIS., (2006), vol. 9, pages 230 - 234 | - HOLLA, V.R; WU, H.; SHI, Q.; MENTER, D.G; DUBOIS, R.N., "Nuclear orphan receptor NR A modulates fatty acid oxidation pathways in colorectal cancer", J. BIOL. CHEM., (2011), vol. 86, pages 30003 - 30009 | - LINHER-MELVILLE, K. ET AL., "Establishing a relationship between prolactin and altered fatty acid p-oxidation via carnitine palmitoyl transferase in breast cancer cells", BMC CANCER, (2011), vol. 4, pages 11 - 56 | - MIGITA, T. ET AL., "ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer", CANCER RES., (2008), vol. 68, doi:doi:10.1158/0008-5472.CAN-08-1235, pages 8547 - 8554, XP055106106 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-08-1235 | - FREZZA, C.; GOTTLIEB, E., "Mitochondria in cancer: not just innocent bystanders", SEMIN. CANCER BIOL., (2009), vol. 19, doi:doi:10.1016/j.semcancer.2008.11.008, pages 4 - 11, XP025959390 DOI: http://dx.doi.org/10.1016/j.semcancer.2008.11.008 | - METALLO, C.M. ET AL., "Reductive glutamine metabolism by IDH mediates lipogenesis under hypoxia", NATURE, (2011), vol. 481, pages 380 - 384 | - ROCHA, C.M. ET AL., "Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma", J. PROTEOME RES., (2011), vol. 10, pages 4314 - 4324 | - CAO, M.; ZHAO, L.; CHEN, H.; XUE, W.; LIN, D., "NMR-based metabolomic analysis of human bladder cancer", ANAL. SCI., (2012), vol. 28, pages 451 - 456 | - ZHANG, L. ET AL., "Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by ( )H nuclear magnetic resonance-based metabonomic profiles", CLIN. BIOCHEM., (2012), vol. 45, pages 1064 - 1069 | - CLYNE, M., "Prostate cancer: Biopsy citrate concentration could predict prostate cancer growth rate", NAT. REV. UROL., (2012), vol. 9, page 123 | - MYCIELSKA, M.E.; PALMER, C.P.; BRACKENBURY, W.J.; DJAMGOZ, M.B., "Expression of Na+-dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na+ channel activity", J. PHYSIOL., (2005), vol. 563, doi:doi:10.1113/jphysiol.2004.079491, pages 393 - 408, XP055178999 DOI: http://dx.doi.org/10.1113/jphysiol.2004.079491 | - MAZUREK, M.P. ET AL., "Molecular origin of plasma membrane citrate transporter in human prostate epithelial cells", EMBO REP., (2010), vol. 11, doi:doi:10.1038/embor.2010.51, pages 431 - 437, XP055178640 DOI: http://dx.doi.org/10.1038/embor.2010.51 | - RATCLIFFE, P.J., "Fumarate hydratase deficiency and cancer: activation of hypoxia signaling?", CANCER CELL, (2007), vol. 11, pages 303 - 305 | - MARIN-VALENCIA, I. ET AL., "Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo", CELL METAB., (2012), vol. 15, doi:doi:10.1016/j.cmet.2012.05.001, pages 827 - 837, XP028520517 DOI: http://dx.doi.org/10.1016/j.cmet.2012.05.001 | - SON, J. ET AL., "Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway", NATURE, (2013), vol. 496, doi:doi:10.1038/nature12040, pages 101 - 105, XP055249836 DOI: http://dx.doi.org/10.1038/nature12040 | - JANG, S.W. ET AL., "Serine/arginine protein-specific kinase promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A", CANCER RES., (2008), vol. 68, pages 4559 - 4570 | - COSTELLO, L.C.; FRANKLIN, R.B., "Citrate metabolism of normal and malignant prostate epithelial cells", UROLOGY, (1997), vol. 50, pages 3 - 12 | - EVANS, A.J., "Alpha-methylacyl CoA racemase (P S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies", J. CLIN. PATHOL., (2003), vol. 6, pages 8 - 897 | - SERKOVA, N.J. ET AL., "The metabolites_citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions", PROSTATE, (2008), vol. 68, doi:doi:10.1002/pros.20727, pages 620 - 628, XP055266303 DOI: http://dx.doi.org/10.1002/pros.20727 | - SINGH, K.K.; DESOUKI, M.M.; FRANKLIN, R.B.; COSTELLO, L.C., "Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues", MOL. CANCER, (2006), vol. 4, pages 5 - 14 | - CARDACI, S.; CIRIOLO, M.R., "TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State", INT. J. CELL BFOF., (2012), page 6 8 | - CUPERLOVIC-CULF, M.; CULF, A.S.; TOUAIBIA, M.; LEFORT, N., "Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype", FUTURE ONCOL., (2012), vol. 8, pages 1315 - 1330 | - LANG, S.A. ET AL., "Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model", INT. J. CANCER, (2007), vol. 120, pages 1803 - 1810 | - VAN DER GOOT, A.T. ET AL., "Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation", PNAS, (2012), vol. 109, pages 14912 - 14917 | - DETTMER, K. ET AL., "Distinct metabolic differences between various human cancer and primary cells", ELECTROPHORESIS, (2013), vol. 34, pages 8 6 - 2847 | - LANTOW, M.; VIERGUTZ, T.; WEISS, D.G.; SIMKO. M., "Comparative study of cell cycle kinetics and induction of apoptosis or necrosis after exposure of human Mono Mac 6 cells to radiofrequency radiation", RADIAT. RES., (2006), vol. 166, pages 539 - 543 |